Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity

COMMENTED

Macular Diseases

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Am J Ophthalmol.

Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, Pertile G

doi: 10.1016/j.ajo.2018.08.004.

Macular DiseasesFurther Publications

Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Acta Ophthalmol

Lupidi M, Schiavon S, Cerquaglia A, Fruttini D, Gujar R, Muzi A, Fiore T, Reibaldi M, Chhablani J, Cagini C

doi: 10.1111/aos.15005

Macular DiseasesRetinal Diseases

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study

Acta Diabetol.

Busch C, Fraser-Bell S, Zur D, Rodríguez-Valdés PJ, Cebeci Z, Lupidi M, Fung AT, Gabrielle PH, Giancipoli E, Chaikitmongkol V, Okada M, Laíns I, Santos AR, Kunavisarut P, Sala-Puigdollers A, Chhablani J, Ozimek M, Hilely A, Unterlauft JD, Loewenstein A, Iglicki M, Rehak M; International Retina Group

doi: 10.1007/s00592-019-01310-z.

Further Publications

Retinal Detachment After Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor

Ophthalmology

Barry GP, Yu Y, Ying GS, Tomlinson LA, Lajoie J, Fisher M, Binenbaum G

doi: 10.1016/j.ophtha.2020.12.028

Macular Diseases

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Ophthalmol Retina.

Ciulla TA, Hussain RM, Pollack JS, Williams DF

doi: 10.1016/j.oret.2019.05.017.

Macular Diseases

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Ophthalmology.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA

doi: 10.1016/j.ophtha.2017.10.010.

Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology

Ophthalmology.

VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR

doi: 10.1016/

Retinal Diseases

Clinical Features and Outcomes of Infants with Retinopathy of Prematurity Who Fail Anti-VEGF Therapy

Retina

Xu LT, Levine DA, Hutchinson AK, Rao P, Hubbard GB 3rd

doi: 10.1097/IAE.0000000000003249

Retinal Diseases

Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Am J Ophthalmol.

Wubben TJ, Johnson MW, Anti-VEGF Treatment Interruption Study Group

doi: 10.1016/j.ajo.2019.03.005.

Related content

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study

Retinal Detachment After Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology

Clinical Features and Outcomes of Infants with Retinopathy of Prematurity Who Fail Anti-VEGF Therapy

Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions